Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019

Background: Retrospective studies using spontaneous reporting system databases have provided a great understanding of adverse drug reactions (ADRs) in the real world, complementing the data obtained from randomized controlled trials. However, there have been few reports on large-scale epidemiological studies on the adverse effects of antipsychotics in Asia. Aim: This study aimed to investigate the characteristics of antipsychotic ADRs using a nationwide pharmacovigilance database. Methods: Data were collected from the Korea Adverse Event Reporting System database between 2010 and 2019. The study subjects were selected using the International Classification of Disease codes for diseases related to psychosis and Electronic Data Interchange codes for amisulpride, aripiprazole, clozapine, haloperidol, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone. The causality assessment of “possible,” “probable,” or “certain” by the World Health Organization–Uppsala Monitoring Center System causality category was selected. All data were descriptively analyzed. Results: In total, 5067 adverse events associated with antipsychotic drugs were reported. The antipsychotics that commonly resulted in ADRs were quetiapine (47.7%), olanzapine (11.3%), and clozapine (10.7%). Serious ADRs were most commonly observed with clozapine. Gastrointestinal and central nervous system problems occurred within a month when ADRs were classified according to the time of onset. In contrast, metabolic and bone marrow-related symptoms occurred after long-term use. Sedation and nausea were the most common ADRs in children and adolescents, whereas constipation and dizziness were common in adults and the elderly. Conclusions: This study extends our knowledge of antipsychotic ADRs in the Asian population.

[1]  A. Young,et al.  Antipsychotics, the heartland of clinical psychopharmacology? , 2021, Journal of psychopharmacology.

[2]  H. Khalil,et al.  Characteristics of voluntary reporting of adverse drug events related to antipsychotics in Australia: 14-year analysis , 2021, Therapeutic advances in drug safety.

[3]  Tae Young Lee,et al.  Effectiveness of antipsychotic drugs in schizophrenia: a 10-year retrospective study in a Korean tertiary hospital , 2020, npj Schizophrenia.

[4]  D. Cohen,et al.  Aripiprazole in Children and Adolescents. , 2020, Journal of child and adolescent psychopharmacology.

[5]  N. Iwata,et al.  Trend survey on adverse event profiles of antipsychotic long-acting injections and oral agents using the Japanese adverse drug event report database , 2020, Psychiatry Research.

[6]  O. Howes,et al.  Making decisions about antipsychotics: a qualitative study of patient experience and the development of a decision aid , 2019, BMC Psychiatry.

[7]  K. Sim,et al.  Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: Findings of the 2016 Research on Asian Psychotropic Prescription Patterns (REAP) survey. , 2019, Asian journal of psychiatry.

[8]  Y. Ahn,et al.  Epidemiology of pharmaceutically treated depression and treatment resistant depression in South Korea , 2019, PloS one.

[9]  Hyun Joo Lee,et al.  Utilisation of medications among elderly patients in intensive care units: a cross-sectional study using a nationwide claims database , 2019, BMJ Open.

[10]  Shin‐Tarng Deng,et al.  Factors associated with adverse drug reaction occurrence and prognosis, and their economic impacts in older inpatients in Taiwan: a nested case–control study , 2019, BMJ Open.

[11]  Mi Hyun Lee,et al.  Trends in prescriptions for sedative–hypnotics among Korean adults: a nationwide prescription database study for 2011–2015 , 2018, Social Psychiatry and Psychiatric Epidemiology.

[12]  T. Stroup,et al.  Management of common adverse effects of antipsychotic medications , 2018, World psychiatry : official journal of the World Psychiatric Association.

[13]  C. Correll,et al.  Tardive dyskinesia risk with first‐ and second‐generation antipsychotics in comparative randomized controlled trials: a meta‐analysis , 2018, World psychiatry : official journal of the World Psychiatric Association.

[14]  D. Song,et al.  Nationwide Epidemiologic Study of Atypical Antipsychotic Use Among Pediatric Population with Mental Illness in Korea. , 2018, Journal of child and adolescent psychopharmacology.

[15]  A. Wheeler,et al.  Clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993–2014 , 2018, Psychopharmacology.

[16]  M. Pompili,et al.  Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine , 2018, Therapeutic advances in drug safety.

[17]  K. Huybrechts,et al.  International trends in antipsychotic use: A study in 16 countries, 2005–2014 , 2017, European Neuropsychopharmacology.

[18]  C. Schneider,et al.  Psychotropic medication use in Australia, 2007 to 2015: Changes in annual incidence, prevalence and treatment exposure , 2017, The Australian and New Zealand journal of psychiatry.

[19]  V. Siskind,et al.  Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis , 2017, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[20]  A. Jablensky,et al.  The 2016 Royal Australian and New Zealand College of Psychiatrists guidelines for the management of schizophrenia and related disorders , 2017, The Medical journal of Australia.

[21]  C. Neoh,et al.  Pharmacovigilance: pharmacists’ perspective on spontaneous adverse drug reaction reporting , 2017, Integrated pharmacy research & practice.

[22]  Amar K. Das,et al.  Differences in Antipsychotic-Related Adverse Events in Adult, Pediatric, and Geriatric Populations , 2017, Cureus.

[23]  G. Juckel,et al.  Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study. , 2016, The lancet. Psychiatry.

[24]  K. Darton,et al.  Results of a pilot cluster randomised trial of the use of a Medication Review Tool for people taking antipsychotic medication , 2016, BMC Psychiatry.

[25]  T. Patel,et al.  Adverse drug reactions in a psychiatric department of tertiary care teaching hospital in India: Analysis of spontaneously reported cases. , 2015, Asian journal of psychiatry.

[26]  G. De Sarro,et al.  Use of atypical antipsychotics in the elderly: a clinical review , 2014, Clinical interventions in aging.

[27]  L. Kim,et al.  A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples , 2014, Epidemiology and health.

[28]  S. Frangou,et al.  Antipsychotics use in children and adolescents: An on-going challenge in clinical practice , 2014, Journal of psychopharmacology.

[29]  M. Sturkenboom,et al.  Torsadogenic Risk of Antipsychotics: Combining Adverse Event Reports with Drug Utilization Data across Europe , 2013, PloS one.

[30]  M. De Hert,et al.  Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review , 2013, Therapeutic advances in psychopharmacology.

[31]  A. Medvedovici,et al.  Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences , 2013, Expert opinion on drug metabolism & toxicology.

[32]  H. Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects , 2013, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[33]  C. Correll,et al.  Safety and tolerability of antipsychotic polypharmacy , 2012, Expert opinion on drug safety.

[34]  A. R. Maher,et al.  Summary of the Comparative Effectiveness Review on Off-Label Use of Atypical Antipsychotics , 2012, Journal of managed care pharmacy : JMCP.

[35]  M. De Hert,et al.  Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study , 2011, BMC gastroenterology.

[36]  S. Leucht,et al.  Second-generation antipsychotics and constipation: A review of the literature , 2011, European Psychiatry.

[37]  R. Tandon Antipsychotics in the treatment of schizophrenia: an overview. , 2011, The Journal of clinical psychiatry.

[38]  S. Leucht,et al.  Clozapine versus other atypical antipsychotics for schizophrenia. , 2010, The Cochrane database of systematic reviews.

[39]  C. Adams,et al.  Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used , 2010, British Journal of Psychiatry.

[40]  J. Muench,et al.  Adverse effects of antipsychotic medications. , 2010, American family physician.

[41]  B. Bégaud,et al.  Antipsychotic prescribing trends: a review of pharmaco‐epidemiological studies , 2010, Acta psychiatrica Scandinavica.

[42]  C. Hong,et al.  Spontaneous reporting of adverse drug events by Korean regional pharmacovigilance centers , 2009, Pharmacoepidemiology and drug safety.

[43]  C. Adams,et al.  Systematic Overview of Cochrane Reviews for Anticholinergic Effects of Antipsychotic Drugs , 2009, Journal of clinical psychopharmacology.

[44]  I. Chaudhry,et al.  Ethnicity and psychopharmacology , 2008, Journal of psychopharmacology.

[45]  R. Ferner,et al.  Ethnic Differences in the Risks of Adverse Reactions to Drugs Used in the Treatment of Psychoses and Depression , 2008, Drug safety.

[46]  N. Choi,et al.  [Adverse drug reaction surveillance system in Korea]. , 2007, Journal of preventive medicine and public health = Yebang Uihakhoe chi.

[47]  Aileen O'Brien Starting Clozapine in the Community , 2004, CNS drugs.

[48]  G. Remington,et al.  Clinical characteristics and associated factors in antipsychotic-induced akathisia of Asian patients with schizophrenia , 2003, Schizophrenia Research.

[49]  F. Micheli,et al.  Quetiapine and Essential Tremor , 2002, Clinical neuropharmacology.

[50]  W. Glazer,et al.  Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. , 2000, The Journal of clinical psychiatry.

[51]  David Taylor,et al.  Tolerability of Atypical Antipsychotics , 2000, Drug safety.

[52]  P. Masand,et al.  Side effects of antipsychotics in the elderly. , 2000, The Journal of clinical psychiatry.

[53]  R. K. Day,et al.  Psychomotor agitation: poorly defined and badly measured. , 1999, Journal of affective disorders.

[54]  J. Adams,et al.  Clozapine dosage, serum levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients. , 1996, Psychopharmacology bulletin.

[55]  G. Hayes,et al.  Clozapine-induced constipation. , 1995, The American journal of psychiatry.

[56]  I. Edwards,et al.  Proposed improvement to the WHO adverse reaction terminology (WHO‐ART) , 1993 .

[57]  R. Meyboom,et al.  Causality classification at pharmacovigilance centres in the european community , 1992 .